Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Gina Fusaro_2023
VIEWPOINTS

Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation on MAA for Opdivo

Shots: Gina gave her views on the acceptance of the sBLA by the US FDA and the validation of the Type II Variation Marketing Authorization Application by the EMA for Opdivo as monotherapy for the treatment of patients with completely resected stage IIB or IIC melanoma She also spoke on the epidemiology of melanoma and…
May 16, 2023

Read more

VIEWPOINTS_Allyson Moellenhoff_2023
VIEWPOINTS

Allyson Moellenhoff, Director of Product Marketing at Kalderos Shares Insights on a New Portal Designed for Drug Manufacturers

Shots: Allyson gave a brief overview of Kalderos and spoke about a new portal designed for drug manufacturers to provide a more efficient way to process drug discount claims She also elaborated on how this Drug Discount Management platform will help drug manufacturers to organize their discounts by taking this data out of Excel spreadsheets…
May 15, 2023

Read more

VIEWPOINTS_Matthew Robinson_2023
VIEWPOINTS

Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets

Shots: Matthew spoke about Immunome’s collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine He also talked about how the partnership with AbbVie can support Immunome’s strategy to maximize the new drug discovery potential of its Discovery Engine…
May 8, 2023

Read more

VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023
VIEWPOINTS

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots: Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platform Mark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
May 4, 2023

Read more

Insights+ Key Biosimilars Events of April 2023
INSIGHTS+

Insights+ Key Biosimilars Events of April 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Sandoz’s Hyrimoz (biosimilar, adalimumab) received EC’s…
May 3, 2023

Read more

VIEWPOINTS_Rick Hawkins1_John McKew Share2_2023
VIEWPOINTS

Rick Hawkins and John McKew Share Views on Interim P-II Data from the Two Trials Evaluating LUM-201 for Moderate Pediatric Growth Hormone Deficiency

Shots: Rick and John spoke about the trial design and the results from the P-II OraGrowtH210 Trial and P-II OraGrowtH212 trial evaluating LUM-201 to treat pediatric growth hormone deficiency They also elaborated on the timeline of the further clinical development of LUM-201 The interview gives an understanding of Lumos Pharma’s vision to develop new therapies…
May 2, 2023

Read more

Thoughtspot_senior_editor
THOUGHTSPOT

8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry

Shots: In the wake of International Labour Day, PharmaShots presents a detailed take on the recent layoffs in the Pharmaceutical Sector with an illustrative graphical analysis Like any sector, the pharmaceutical industry operates on some nuance and intricate aspects that ensure smooth operations. Factors like digitalization, patent expiry, growing competition, and others put direct or…
May 1, 2023

Read more

Load more